Clinical dose findings of sitafloxacin treatment: Pharmacokinetic- pharmacodynamic analysis of two clinical trial results for community-acquired respiratory tract infections

Shigeru Kohno, Yoshihito Niki, Jun Ichi Kadota, Katsunori Yanagihara, Mitsuo Kaku, Akira Watanabe, Nobuki Aoki, Seiji Hori, Jiro Fujita, Yusuke Tanigawara

Research output: Contribution to journalArticle

13 Citations (Scopus)


The adequacy of sitafloxacin clinical dose regimens was assessed by comparing the efficacy of the administration of 100 mg sitafloxacin once daily (100 mg qd group) and 50 mg sitafloxacin twice daily (50 mg bid group). Patients with respiratory tract infections caused by pneumococci were orally treated with sitafloxacin (100 mg qd or 50 mg bid) for 7 days. The clinical efficacy, pneumococci eradication rate, safety, and pharmacokinetic and pharmacodynamic indices of the two groups were then assessed. The clinical efficacy was 93.5 % in both groups. The pneumococci eradication rate was 98.2 % in the 100 mg qd group and 92.7 % in the 50 mg bid group. The mean of the free AUC 0-24h divided by the minimum inhibitory concentration (MIC) (fAUC0-24h/MIC) did not differ significantly between the 100 mg qd (103.24) and the 50 mg bid groups (105.25). The mean of the free C peak divided by the MIC (fC peak/MIC) was higher in the 100 mg qd group (10.19) than in the 50 mg bid group (6.53). The pathogen eradication rate was 98.9 % (89/90) when the fAUC0-24h/MIC was greater than 30, and the eradication rate was 98.9 % (89/90) when the fC peak/MIC was greater than 2. The incidences of adverse drug reactions were 33.7 % in the 100 mg qd group and 40.4 % in the 50 mg bid group. No obvious differences in the efficacy and safety were observed between the dosage groups. For cases in which a sufficiently high C peak is necessary to ensure the susceptibility of the pathogens to the drug, 100 mg sitafloxacin once daily should be administered.

Original languageEnglish
Pages (from-to)486-494
Number of pages9
JournalJournal of Infection and Chemotherapy
Issue number3
Publication statusPublished - 2013 Jun



  • Fluoroquinolone
  • Pneumococci
  • Randomized study

ASJC Scopus subject areas

  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases

Cite this